List view / Grid view




Epidarex Capital launches Nodthera Limited

28 July 2016 | By Epidarex Capital

Epidarex Capital announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome...


PIM/FLT3 dual inhibition

13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.

In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...


Selvita opens new research site in Poland

4 February 2016 | By Victoria White

The new site will be located at in the Wielkopolska Centre of Advanced Technologies, Poznan, and commence research activities in the summer of 2016...


Selvita expands its operations into the US

21 September 2015 | By Victoria White

Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...